FDA again delays review of Amicus rare disease drug

[cafead]

via The Food and Drug Administration has for a second time this year delayed its review of Amicus Therapeutics’ experimental treatment for Pompe disease, deferring action until the agency can inspect the drug’s manufacturing facilities in China.

article source